Professor Mark James McKeage



Professor Mark McKeage is a physician-scientist with many years experience as research group leader (Cancer Clinical Pharmacology Research Group), practising medical oncologist, clinical trial investigator, graduate student thesis supervisor, and teacher of pharmacology, oncology and clinical medicine. He has over 100 research articles, over 3500 citations and an H-index of 33. His current research seeks to understand mechanisms and develop treatments for platinum drug neurotoxicity and transport-mediated resistance, and to improve lung cancer healthcare via novel genetic testing strategies and targeted therapies.

Currently Professor in the Department of Pharmacology and Clinical Pharmacology, and Co-director of the Auckland Cancer Society Research Centre, he previously he worked at The Institute of Cancer Research and Royal Marsden Hospital (London UK) and the Prince of Wales Hospital, a teaching hospital of the University of New South Wales. 

Visit the Cancer Clinical Pharmacology Group website

Selected publications and creative works (Research Outputs)

  • McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., ... Xu, L. (2018). Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Target Oncol, 13 (1), 89-98. 10.1007/s11523-017-0543-0
    Other University of Auckland co-authors: Michael Jameson
  • Cui, H., Zhang, A. J., McKeage, M. J., Nott, L. M., Geraghty, D., Guven, N., & Liu, J. J. (2017). Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. Journal of Inorganic Biochemistry, 177, 249-258. 10.1016/j.jinorgbio.2017.04.022
  • (2017). EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Targeted Oncology, 12 (5), 663-675. 10.1007/s11523-017-0515-4
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood, Don Love, Phyu Aye
  • Shepherd, P., Sheath, K. L., Tin Tin, S., Khwaounjoo, P., Aye, P. S., Li, A., ... Elwood, J. M. (2017). Lung cancer mutation testing: A clinical retesting study of agreement between a real-time PCR and a mass spectrometry test. Oncotarget, 8 (60), 101437-101451. 10.18632/oncotarget.21023
    Other University of Auckland co-authors: Sandar Tin Tin, Don Love, Mark Elwood, Phyu Aye
  • Cho, B. C., Kim, D. W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., ... Ardizzoni, A. (2017). ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 12 (9), 1357-1367. 10.1016/j.jtho.2017.07.005
  • Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., ... Rosell, R. (2017). Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 377 (9), 829-838. 10.1056/NEJMoa1704795
  • Han, C. H., Khwaounjoo, P., Hill, A. G., Miskelly, G. M., & McKeage, M. (2017). Predicting effects on oxaliplatin clearance: In vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation. Scientific Reports, 7 (1)10.1038/s41598-017-04383-4
    Other University of Auckland co-authors: Gordon Miskelly, Catherine Han
  • Han, C. H., Kilfoyle, D. H., Hill, A. G., Jameson, M. B., & McKeage, M. J. (2016). Preventing oxaliplatin-induced neurotoxicity: Rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. Expert Opinion on Drug Metabolism & Toxicology, 12 (12), 1479-1490. 10.1080/17425255.2016.1223625
    Other University of Auckland co-authors: Michael Jameson, Catherine Han


Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 2, Room 236A
New Zealand

Web links